« Previous
Next »
The American Journal of Pathology
Volume 178, Issue 4
, Pages 1478-1488
, April 2011
Genome and Transcriptome Profiles of CD133-Positive Colorectal Cancer Cells
| Title | About | Type | File Size |
|---|---|---|---|
| Supplemental Figure S1 |
A, B: Control group. From eight FFPE blocks, two needle biopsies of approximately 0.5-cm distance in either the CD133+ or CD133− tumor area were cut and analyzed with aCGH for genetic differences (E). After immunohistochemistry for CD133, (C) the CD133+ and CD133− cells were laser microdissected (D) and analyzed with array comparative genomic hybridization for genetic differences (E). |
|
0 MB |
| Supplemental Figure S2 |
Staining was performed according to a conventional set-up used for primary CRC cells in the literature.25,26 |
|
0 MB |
| Supplemental Figure S3 |
The proportion of CD133+/CD133− in HCT-116 cultures was not significantly different to the set-up in Supplemental Figure 2. The staining procedure allowed identifying small changes in the CD133 distribution throughout culturing. In short-term cultures after separation, the populations preserved their CD133 expression profile. At later stages, we observed a redistribution of the CD133+ and CD133− cell populations in the cultured CD133+ fraction. Given are the number of passages (P) and of cumulative population doublings (CPD) after sorting. The culture doubling time for the two fractions was identical. |
|
0 MB |
| Supplemental Figure S4 |
CD133+/CD133− distributions after tumor growth in xenografts derived from injection of either CD133+ or CD133− subpopulation estimated by FACS (A) after HT−29 cell injection and (B) after HCT 116 cell injection. |
|
0 MB |
| Supplemental Table S1 |
|
0 MB | |
| Supplemental Table S2 |
|
0 MB | |
| Supplemental Table S3 |
|
0 MB |
Please note that add-on components may require plug-in applications.
Supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. T.G. is supported by a fellowship within the post doctorate program of the Mildred Scheel Foundation. The work performed by the group of LAKS (Tumor Pathophysiology, OncoRay) was supported by the German Research Foundation (DFG) through a grant (KU 971/7-1). OncoRay is funded by the Bundesministerium fuer Bildung und Forschung in the program “Center for Innovation Competence.”
Supplemental material for this article can be found http://ajp.amjpathol.org or at doi:10.1016/j.ajpath.2010.12.036.
PII: S0002-9440(11)00026-5
doi: 10.1016/j.ajpath.2010.12.036
© 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The American Journal of Pathology
Volume 178, Issue 4
, Pages 1478-1488
, April 2011
